EICHOR
● Recruiting
Molecularly Redefining Small Bowel Adenocarcinoma to Accelerate Precision Patient Care
Condition: Small Bowel Adenocarcinoma · Sponsor: Copenhagen University Hospital at Herlev
About this study
Small bowel adenocarcinoma is a rare malignancy, and there is limited knowledge about its optimal clinical management and molecular background. The SBAMOL study is an observational biomarker study that aims to identify prognostic and predictive biomarkers. This effort is intended to lay the groundwork for personalized medicine tailored to this specific patient group.
This description comes directly from the study's public registry record.
Talk to the study team
Dan Høgdall, MD PhD · 004538681954 · danhog01@regionh.dk
Jakob HV Schou, MD · 004538682985 · jakob.hagen.vasehus.schou@regionh.dk
Always discuss trial participation with your own doctor first.
Locations (3)
| Department of Oncology, Aarhus University Hospital | Aarhus N, Denmark | Recruiting |
| Department Surgical Gastroenterology, Copenhagen University Hospital - Rigshospitalet | Copenhagen Ø, Denmark | Recruiting |
| Department of Oncology Copenhagen University Hospital - Herlev and Gentofte | Herlev, Denmark | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06234306